Loading…
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-22M | $-22M | $-19M | -280.5% | - | - |
| 2024 | $0M | $-27M | $-27M | $-22M | -26189.1% | - | - |
| 2023 | $0M | $-25M | $-25M | $-22M | 24.8% | - | - |
| 2022 | $0M | $-20M | $-20M | $-18M | 26.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 20.21 | 24.97 | 25.16 | 22.50 |
| Operating Income | -20.21 | -24.97 | -25.16 | -22.50 |
| EBITDA | -20.14 | -24.70 | -27.27 | -22.21 |
| EBIT | -20.14 | -24.70 | -27.27 | -22.21 |
| Pretax Income | -20.16 | -24.74 | -27.29 | -22.23 |
| Net Income | -20.16 | -24.74 | -27.29 | -22.23 |
| Net Income Common Stockholders | -20.16 | -24.74 | -27.29 | -22.23 |
| Total Expenses | 20.21 | 24.97 | 25.16 | 22.50 |
| Interest Expense | 0.02 | 0.04 | 0.02 | 0.02 |
| Interest Income | 0.03 | 0.35 | 0.22 | 0.29 |
| Research And Development | 16.39 | 21.71 | 18.68 | 10.29 |
| Selling General And Administration | 3.82 | 3.27 | 6.48 | 12.20 |
| Normalized EBITDA | -20.18 | -24.62 | -27.53 | -22.21 |
| Normalized Income | -20.20 | -24.66 | -27.55 | -22.23 |
| Basic EPS | -1.34 | -1.29 | -3.26 | 0 |
| Diluted EPS | -1.34 | -1.29 | -3.26 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0.04 | -0.08 | 0.26 | 0 |
| Total Unusual Items Excluding Goodwill | 0.04 | -0.08 | 0.26 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -20.16 | -24.74 | -27.29 | -22.23 |
| Net Interest Income | 0.01 | 0.31 | 0.20 | 0.27 |
| Net Income From Continuing And Discontinued Operation | -20.16 | -24.74 | -27.29 | -22.23 |
| Total Operating Income As Reported | -20.21 | -24.97 | -25.16 | -22.50 |
| Diluted Average Shares | 15.03 | 19.11 | 8.37 | 0 |
| Basic Average Shares | 15.03 | 19.11 | 8.37 | 0 |
| Diluted NI Availto Com Stockholders | -20.16 | -24.74 | -27.29 | -22.23 |
| Net Income Including Noncontrolling Interests | -20.16 | -24.74 | -27.29 | -22.23 |
| Net Income Continuous Operations | -20.16 | -24.74 | -27.29 | -22.23 |
| Other Income Expense | 0.04 | -0.08 | -2.33 | 0 |
| Other Non Operating Income Expenses | 0 | 0 | -2.59 | 0 |
| Gain On Sale Of Security | 0.04 | -0.08 | 0.26 | 0 |
| Net Non Operating Interest Income Expense | 0.01 | 0.31 | 0.20 | 0.27 |
| Interest Expense Non Operating | 0.02 | 0.04 | 0.02 | 0.02 |
| Interest Income Non Operating | 0.03 | 0.35 | 0.22 | 0.29 |
| General And Administrative Expense | 3.82 | 3.27 | 6.48 | 12.20 |
| Other Gand A | 1.24 | 1.44 | 2.71 | 4.60 |
| Salaries And Wages | 2.58 | 1.83 | 3.77 | 7.61 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Actuate Therapeutics, Inc. Common stockthis co. | ACTU | $68M | - | 8.45 | -280.5% | - |
| biote Corp. | BTMD | $83M | 3.00 | -1.16 | -53.7% | 4.32 |
| Gossamer Bio, Inc. | GOSS | $82M | - | -0.67 | 138.8% | -0.91 |
| Outset Medical, Inc. | OM | $77M | - | 0.60 | -64.3% | -0.14 |
| aTyr Pharma, Inc. | ATYR | $75M |
| - |
| 1.11 |
| -110.2% |
| -0.11 |
| DocGo Inc. | DCGO | $70M | - | 0.48 | -144.9% | -0.41 |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Pulmonx Corporation | LUNG | $51M | - | 0.92 | -99.8% | -0.71 |
| Accuray Incorporated | ARAY | $50M | - | 0.94 | -2.0% | -107.66 |
| Peer Median | - | 3.00 | 0.54 | -59.0% | -0.56 | |